Maddy summaryThis bill directs the Maryland Department of Health to form a group of stakeholders to study whether the qualifications for the executive director of the State Board of Nursing should change. The workgroup will examine how well the Board currently functions, compare the current requirements with those of other state health boards, and review qualifications used by other nursing boards. By December 1, 2024, the group must submit a report with its findings and any recommendations to the state legislature. The bill does not immediately change the job requirements but instead creates a process to review them before the current rules expire.
Del. Ken Kerr
Sponsored bills
Maddy summaryThis Maryland bill requires health insurers and health plans to cover specific breast and lung cancer screening services without imposing copayments, coinsurance, or deductibles, with the exception of high-deductible health plans. For breast cancer, the law expands the definition of supplemental screening to include image-guided breast biopsies and mandates that these services be covered at the same cost as standard breast cancer screening. Regarding lung cancer, the bill ensures coverage for recommended screenings and necessary follow-up diagnostic imaging, such as CT scans and biopsies, while explicitly prohibiting plans from requiring prior authorization for these services. These coverage requirements apply to all health policies issued, delivered, or renewed in the state on or after January 1, 2025.
Maddy summaryThis Maryland bill updates health insurance rules to improve how prior authorization requests are handled and to ensure patients receive clearer cost information. It requires insurance companies to create online systems that allow doctors to submit and receive approval for drug coverage electronically, while also displaying real-time out-of-pocket costs and cheaper medication options at the point of prescribing. The law further prohibits insurers from charging fees for accessing these digital tools and restricts their ability to use provider data without consent. Additionally, the bill removes prior authorization requirements for specific prescription drugs used to treat opioid use disorder, such as methadone, buprenorphine, and naltrexone. These changes aim to streamline the approval process and increase transparency for both healthcare providers and insured individuals.